Back from the brink: EGFR inhibition in gastroesophageal cancer

Mark R. Openshaw; David J. Pinato; Nicola Valeri

doi:10.1158/1078-0432.CCR-21-0533

Back from the brink: EGFR inhibition in gastroesophageal cancer

Mark R. Openshaw, David J. Pinato, Nicola Valeri

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

Gastroesophageal adenocarcinomas (GEA) remain difficult to treat with limited targeted therapeutics. Negative results from randomized trials of EGFR inhibitors (EGFRi) in patients with molecularly unselected GEA have hampered the development of EGFRi in the gastroesophageal cancer space. A recent study reopens the game.

Lingua originale	Inglese
pagine (da-a)	2964-2966
Numero di pagine	3
Rivista	Clinical Cancer Research
Volume	27
Numero di pubblicazione	11
DOI	https://doi.org/10.1158/1078-0432.CCR-21-0533
Stato di pubblicazione	Pubblicato - 1 giu 2021

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1158/1078-0432.CCR-21-0533

Altri file e collegamenti

Link to publication in Scopus

Cita questo

@article{f1d0fb7690f54929a77578d64d687a51,

title = "Back from the brink: EGFR inhibition in gastroesophageal cancer",

abstract = "Gastroesophageal adenocarcinomas (GEA) remain difficult to treat with limited targeted therapeutics. Negative results from randomized trials of EGFR inhibitors (EGFRi) in patients with molecularly unselected GEA have hampered the development of EGFRi in the gastroesophageal cancer space. A recent study reopens the game.",

author = "Openshaw, {Mark R.} and Pinato, {David J.} and Nicola Valeri",

note = "Publisher Copyright: {\textcopyright} 2021 American Association for Cancer Research.",

year = "2021",

month = jun,

day = "1",

doi = "10.1158/1078-0432.CCR-21-0533",

language = "English",

volume = "27",

pages = "2964--2966",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "11",

}

TY - JOUR

T1 - Back from the brink

T2 - EGFR inhibition in gastroesophageal cancer

AU - Openshaw, Mark R.

AU - Pinato, David J.

AU - Valeri, Nicola

PY - 2021/6/1

Y1 - 2021/6/1

N2 - Gastroesophageal adenocarcinomas (GEA) remain difficult to treat with limited targeted therapeutics. Negative results from randomized trials of EGFR inhibitors (EGFRi) in patients with molecularly unselected GEA have hampered the development of EGFRi in the gastroesophageal cancer space. A recent study reopens the game.

AB - Gastroesophageal adenocarcinomas (GEA) remain difficult to treat with limited targeted therapeutics. Negative results from randomized trials of EGFR inhibitors (EGFRi) in patients with molecularly unselected GEA have hampered the development of EGFRi in the gastroesophageal cancer space. A recent study reopens the game.

UR - http://www.scopus.com/inward/record.url?scp=85106970456&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-21-0533

DO - 10.1158/1078-0432.CCR-21-0533

M3 - Article

SN - 1078-0432

VL - 27

SP - 2964

EP - 2966

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 11

ER -

Back from the brink: EGFR inhibition in gastroesophageal cancer

Abstract

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo